1. High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: A randomized, double-blinded placebo-controlled trial
- Author
-
Katie Wynne, Christine J. O'Neill, Rosemary Carroll, Christopher W. Rowe, Jacqueline Hawthorne, Cino Bendinelli, and Sam Arthurs
- Subjects
musculoskeletal diseases ,Adult ,Male ,medicine.medical_specialty ,Calcium-Regulating Hormones and Agents ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Premedication ,Placebo-controlled study ,Parathyroid hormone ,030209 endocrinology & metabolism ,Placebo ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Endocrinology ,Internal medicine ,Preoperative Care ,medicine ,Vitamin D and neurology ,Humans ,Hypocalcaemia ,Cholecalciferol ,Hypocalcemia ,business.industry ,Thyroidectomy ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Treatment Outcome ,chemistry ,030220 oncology & carcinogenesis ,Parathyroid gland ,Female ,business - Abstract
OBJECTIVE Post-thyroidectomy hypocalcaemia is a significant cause of morbidity and prolonged hospitalization, usually due to transient parathyroid gland damage, treated with calcium and vitamin D supplementation. We present a randomized, double-blinded placebo-controlled trial of preoperative loading with high-dose cholecalciferol (300 000 IU) to reduce post-thyroidectomy hypocalcaemia. PATIENTS AND MEASUREMENTS Patients (n = 160) presenting for thyroidectomy at tertiary hospitals were randomized 1:1 to cholecalciferol (300 000 IU) or placebo 7 days prior to thyroidectomy. Ten patients withdrew prior to surgery. The primary outcome was post-operative hypocalcaemia (corrected calcium
- Published
- 2018